Clinical impact of the immunome in lymphoid malignancies: The role of myeloid-derived suppressor cells

Frontiers in Oncology

Volumn 5, Issue MAY, 2015, Pages

  Vetro, Calogero ^a   Romano, Alessandra ^a   Ancora, Flavia ^a   Coppolino, Francesco ^b   Brundo, Maria V ^a   Raccuia, Salvatore A ^a,c   Puglisi, Fabrizio ^a   Tibullo, Daniele ^a   Cava, Piera La ^a   Giallongo, Cesarina ^a   Parrinello, Nunziatina L ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Lymphoma; MDSCs; Microenvironment; Prognostication

Indexed keywords

ARGINASE 1; CD11B ANTIGEN; CD14 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CELL SURFACE MARKER; CYCLOOXYGENASE 2; GAMMA INTERFERON; HLA DR ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; BONE MARROW; CANCER PROGNOSIS; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; LYMPHOMA; MOLECULAR INTERACTION; MONOCYTOSIS; MYELOID DERIVED SUPPRESSOR CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84934278908     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00104     Document Type: Review

References (56)

1. Bizzarri M, Cucina A. Tumor and the microenvironment: a chance to reframe the paradigm of carcinogenesis? Biomed Res Int (2014) 2014:934038. doi: 10.1155/2014/934038
2. Romano A, Conticello C, Cavalli M, Vetro C, La Fauci A, Parrinello NL, et al.Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int (2014) 2014:198539. doi:10.1155/2014/198539
3. Romano A, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, et al.Immunological deregulation in classic Hodgkin lymphoma. Mediterr J Hematol Infect Dis (2014) 6:e2014039. doi:10.4084/MJHID.2014.039
4. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al.Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 351:2159-69. doi:10.1056/NEJMoa041869
5. Fozza C, Corda G, Virdis P, Contini S, Barraqueddu F, Galleu A, et al.Derangement of the T-cell repertoire in patients with B-cell non-Hodgkin's lymphoma. Eur J Haematol (2014) 94(4):298-309. doi:10.1111/ejh.12417
6. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, et al.Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol (2009) 27:31-9. doi:10.1002/hon.878
7. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol (2010) 221:248-63. doi:10.1002/path.2711
8. Sharma A, Khan R, Joshi S, Kumar L, Sharma M. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma (2010) 51:920-7. doi:10.3109/10428191003699563
9. Bertilaccio MT, Scielzo C, Muzio M, Caligaris-Cappio F. An overview of chronic lymphocytic leukaemia biology. Best Pract Res Clin Haematol (2010) 23:21-32. doi:10.1016/j.beha.2009.12.005
10. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol (2011) 29:1812-26. doi:10.1200/JCO.2010.32.8401
11. Hudnall SD, Betancourt E, Barnhart E, Patel J. Comparative flow immunophenotypic features of the inflammatory infiltrates of Hodgkin lymphoma and lymphoid hyperplasia. Cytometry B Clin Cytom (2008) 74:1-8. doi:10.1002/cyto.b.20376
12. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica (2008) 93:193-200. doi:10.3324/haematol.11702
13. Alvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, et al.Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res (2005) 11:1467-73. doi:10.1158/1078-0432.CCR-04-1869
14. Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, et al.Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol (2013) 31:256-62. doi:10.1200/JCO.2011.39.9881
15. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, et al.In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood (2006) 107:3940-9. doi:10.1182/blood-2005-09-3671
16. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, et al.Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood (2010) 115:5385-92. doi:10.1182/blood-2009-10-246660
17. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, et al.Dysfunctional T regulatory cells in multiple myeloma. Blood (2006) 107:301-4. doi:10.1182/blood-2005-08-3101
18. Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, et al.Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk Lymphoma (2013) 55(5):1090-8. doi:10.3109/10428194.2013.825905
19. Beyer M, Classen S, Endl E, Kochanek M, Weihrauch MR, Debey-Pascher S, et al.Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3. Clin Dev Immunol (2011) 2011:734036. doi:10.1155/2011/734036
20. Wang M, Tian T, Yu S, He N, Ma D. Th17 and Treg cells in bone related diseases. Clin Dev Immunol (2013) 2013:203705. doi:10.1155/2013/203705
21. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood (2010) 116:3554-63. doi:10.1182/blood-2010-05-283895
22. Shen CJ, Yuan ZH, Liu YX, Hu GY. Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma. J Int Med Res (2012) 40:556-64. doi:10.1177/147323001204000217
23. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica (2011) 96:186-9. doi:10.3324/haematol.2010.033316
24. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al.High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol (2008) 26:440-6. doi:10.1200/JCO.2007.12.8298
25. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta (2009) 1796:11-8. doi:10.1016/j.bbcan.2009.02.004
26. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood (2009) 113:3139-46. doi:10.1182/blood-2008-12-172825
27. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, et al.Cellular and molecular pathways linking inflammation and cancer. Immunobiology (2009) 214:761-77. doi:10.1016/j.imbio.2009.06.014
28. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al.Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 362:875-85. doi:10.1056/NEJMoa0905680
29. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al.Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood (2012) 120:3280-7. doi:10.1182/blood-2012-04-421057
30. Ribatti D, Moschetta M, Vacca A. Macrophages in multiple myeloma. Immunol Lett (2014) 161:241-4. doi:10.1016/j.imlet.2013.12.010
31. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, et al.Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol (2012) 23:736-42. doi:10.1093/annonc/mdr157
32. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12:253-68. doi:10.1038/nri3175
33. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, et al.Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol (2010) 72:540-7. doi:10.1111/j.1365-3083.2010.02463.x
34. Nagaraj S, Collazo M, Corzo CA, Youn JI, Ortiz M, Quiceno D, et al.Regulatory myeloid suppressor cells in health and disease. Cancer Res (2009) 69:7503-6. doi:10.1158/0008-5472.CAN-09-2152
35. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, et al.Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol (2012) 189:5602-11. doi:10.4049/jimmunol.1201018
36. Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res (2009) 69:5514-21. doi:10.1158/0008-5472.CAN-08-4625
37. Capuano G, Rigamonti N, Grioni M, Freschi M, Bellone M. Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol (2009) 10:1. doi:10.1186/1471-2172-10-1
38. Eisenstein S, Coakley BA, Briley-Saebo K, Ma G, Chen HM, Meseck M, et al.Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res (2013) 73:5003-15. doi:10.1158/0008-5472.CAN-12-1597
39. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 181:5791-802. doi:10.4049/jimmunol.181.8.5791
40. Romano A, Vetro C, Adriani M. Advances in understanding regulatory myeloid cells. Cancer Biol Ther (2011) 11:923-6. doi:10.4161/cbt.11.11.15541
41. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9:162-74. doi:10.1038/nri2506
42. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 182:4499-506. doi:10.4049/jimmunol.0802740
43. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al.Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 64:5839-49. doi:10.1158/0008-5472.CAN-04-0465
44. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al.Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 13:828-35. doi:10.1038/nm1609
45. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol (2010) 40:2969-75. doi:10.1002/eji.201040895
46. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 222:162-79. doi:10.1111/j.1600-065X.2008.00602.x
47. Parrinello N, Di Raimondo F, Romano A. Myeloid derived suppressor cells in multiple myeloma. Exp Rev Immunol Vaccine (2014) 1:14-20.
48. Tadmor T, Attias D, Polliack A. Myeloid-derived suppressor cells - their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol (2011) 153:557-67. doi:10.1111/j.1365-2141.2011.08678.x
49. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood (2011) 117:872-81. doi:10.1182/blood-2010-05-283820
50. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 68:5439-49. doi:10.1158/0008-5472.CAN-07-6621
51. Tadmor T, Fell R, Polliack A, Attias D. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol (2013) 31:65-71. doi:10.1002/hon.2019
52. Vetro C, Romano A, Fiumara P, Donnarumma D, Chiarenza A, Figuera A, et al. Inflammatory markers assessment at diagnosis can improve the risk assessment of Hodgkin lymphoma patients. Annals of Oncology. Oxford: Oxford University Press (2011). p. 238-238.
53. Romano A, Vetro C, Parrinello NL, Donnarumma D, Chiarenza A, Figuera A, et al.Prognostic value of myeloid impairment in Hodgkin's lymphoma. Annals of Oncology. Oxford: Oxford University Press (2011). p. 143-143.
54. Romano A, Parrinello N, Vetro C, La Cava P, Giallongo C, Tibullo A, et al. Myeloid cells exert immunosuppressive activity and have prognostic value in Hodgkin lymphoma. Blood (2013) 122:4238-4238.
55. Romano A, Parrinello N, Vetro C, La Cava P, Donnarumma D, Conticello C, et al. Absolute count of myeloid derived suppressor cells (MDSC) is able to predict the response to early-PET in Hodgkin lymphoma. Blood. Washington, DC: American Society of Hematology (2010). p. 1585-6.
56. Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, et al.Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol (2014) 168(5):689-700. doi:10.1111/bjh.13198